Advertisement

Topics

AbbVie’s Mavyret Approved by FDA for Treatment of Hepatitis C in All Major Genotypes

16:16 EDT 3 Aug 2017 | Speciality Pharma Journal

NORTH CHICAGO, Ill., Aug. 3, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved MAVYRET™ (glecaprevir/pibrentasvir), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6). MAVYRET is an 8-week, pan-genotypic treatment for patients without cirrhosis and who …

Original Article: AbbVie’s Mavyret Approved by FDA for Treatment of Hepatitis C in All Major Genotypes

NEXT ARTICLE

More From BioPortfolio on "AbbVie’s Mavyret Approved by FDA for Treatment of Hepatitis C in All Major Genotypes"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...